icon
An official government website affiliated with the Government of the Kingdom of Saudi Arabia.
icon Wed 18 Nov 2026
Beta version
icon
Official Saudi government website domains end with gov.sa

All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.

icon
Official Reliable websites use HTTPS

Ensure the website is using the HTTPS protocol.

icon

Registered with the Digital Government Authority under number:

20250831619
Suggestions

SFDA CEO: Vision 2030 Has Established a Sustainable National Model to Accelerate Patient Access to Innovative Therapies

Food
Drugs
Medical Devices
Cosmetics

SFDA CEO: Vision 2030 Has Established a Sustainable National Model to Accelerate Patient Access to Innovative Therapies

icon

H.E. Dr. Hisham S. Aljadhey, CEO of the Saudi Food and Drug Authority (SFDA), emphasized the importance of strengthening international cooperation among regulatory authorities and harnessing innovation to advance regulatory frameworks. He noted that these efforts are essential to keeping pace with rapid developments in the drug sector and accelerating patient access to innovative treatments tailored to their needs, particularly for people living with rare diseases or requiring specialized therapies.

The SFDA CEO made these remarks during a panel discussion titled “Leading Together – How to Shape the Future of Global Regulation Through Collaboration and Regulatory Innovation,” held as part of the DIA-MHRA Global Summit in London on November 16–17.

Dr. Aljadhey stated that, under Saudi Vision 2030, Saudi Arabia continues to develop an integrated and sustainable regulatory model that enhances oversight efficiency, strengthens the ability to anticipate challenges and adapt to change, and prioritizes patient protection. This approach aims to ensure timely access to safe and effective medical products that address patients’ individual health needs.

Dr. Aljadhey further noted that Saudi Arabia’s regulatory progress reflects coordinated national efforts, sustained investment in research and innovation, the adoption of emerging technologies in biopharmaceutical development and manufacturing, and the expansion of data infrastructure. Collectively, these efforts have strengthened the healthcare sector’s capabilities and enhanced regulatory assessment tools, enabling them to stay aligned with scientific and technological advances in drug development.

The SFDA’s participation in the summit highlights its commitment to strengthening Saudi Arabia’s presence in international regulatory forums and contributing to the future of global drug regulation. It also provides an opportunity to exchange expertise and best practices with regulatory counterparts worldwide and support innovation in medical products, advancing patient safety and facilitating timely access to safe and effective treatments.

DSC_6799.jpg.jpeg
DSC_7306.JPG.jpeg
DSC_7360.jpg.jpeg